Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Cell Therapy Market Evolve in Terms of Growth and Size by 2029?

In recent times, the rheumatology therapeutics market has witnessed a steady escalation in its size. The market, valued at $42.4 billion in 2024, is predicted to reach $44.18 billion in 2025, fueled by a compound annual growth rate (CAGR) of 4.2%. The historical growth in the market is due to the higher instances of rheumatologic disorders, an increase in the global aging population, enhanced awareness regarding treatment alternatives, advancements in biological therapies, and the extension of healthcare accessibility in developing markets.

The market for rheumatology therapeutics is projected to experience consistent expansion in the upcoming years, reaching “$52.25 billion in 2029 with a compound annual growth rate (CAGR) of 4.3%. Prospective growth in this period is linked to the adoption of personalized medicine, increased use of biosimilars in rheumatology, a surge in research and development investments, the incorporation of digital healthcare tech, and the green light for new therapy alternatives. Core trends for this predicted period encompass the rise in telemedicine and remote patient monitoring solutions, the broadening of targeted treatments for particular rheumatic conditions, prioritization of patient-focused care strategies, enlargement of biologic therapies beyond monoclonal antibodies, and the uptake of value-driven pricing structures.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What factors are expected to fuel Cell Therapy market growth in the coming years?

The surge in chronic diseases has contributed to the growth of the cell therapy market. The US Centers for Disease Control and Prevention (CDC) characterizes chronic disease as an illness lasting a year or more that necessitates medical care, hinders daily activities, or both. This includes conditions like heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells have the potential to assist patients with conditions such as spinal cord injuries, type 1 diabetes, Parkinson’s disease, heart disease, cancer, and osteoarthritis. As an illustration, in July 2024, the Centers for Disease Control and Prevention (CDC), a national public health organization in the U.S., disclosed significant advancements in public health initiatives. Heart disease or stroke lead to the death of over 944,800 Americans annually, representing more than one-third of all deaths. In the U.S., yearly cancer diagnoses are approximately 1.7 million individuals, with over 600,000 ultimately succumbing to the disease, making it the second leading cause of death. Furthermore, over 38 million Americans have diabetes, and another 98 million adults are prediabetic, thus increasing their potential for developing type 2 diabetes. Diabetes can trigger serious complications like heart disease, renal failure, and blindness. Meanwhile, obesity affects 20% of children and 42% of adults, thereby increasing susceptibility to chronic diseases such as type 2 diabetes, heart disease, and certain cancers. The escalating prevalence of chronic diseases has intensified the need for cell therapies, thereby facilitating the expansion of the cell therapy market.

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

What Trends Are Currently Influencing Growth In The Cell Therapy Market?

Top-tier firms in the rheumatology therapeutics market are focusing on the development of innovative solutions, such as intravenous (IV) formulations. This strategy is intended to boost treatment effectiveness and improve patient experience. IV formulations involve the direct administration of medication or substances into a vein using a needle or catheter. For example, in October 2023, the US Food and Drug Administration (FDA) granted approval to Cosentyx, an IV formulation from Novartis AG, a renowned pharmaceutical company based in Switzerland. This particular version of Cosentyx has the exclusive approval for treating adult patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). By specifically blocking interleukin-17A (IL-17A), it serves as the sole non-tumor necrosis factor alpha (TNF-a) IV treatment option for these diseases.

What Are The Most Active Companies In The Cell Therapy Market Today?

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Which Regional Markets Are Attracting The Most Investment In Cell Therapy?

North America was the largest region in the rheumatology therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model